Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
about
Conditioning regimens for hematopoietic cell transplantation: one size does not fit allMulti-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningMulticenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG).Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.Allogeneic hematopoietic cell transplantation in septuagenariansA Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis.Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and muTherapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial.Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patientsBlood Research: a new journey of passion with harmony beyond Asia onto the worldPrognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation.Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Reduced-intensity conditioned allogeneic SCT in adults with AML.Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT.Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EChimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation.Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients
P2860
Q33917170-BFE19745-939D-4701-8F67-59511653E031Q34402494-1D15E8C0-0853-491A-9B5D-A82AD55DC822Q34544439-189473A5-97B2-4C54-B22C-14CCEC82C0C4Q34807259-50A697A1-37EF-427B-BD78-BA4BE7CA94D5Q35647641-579E127F-7526-4617-85CA-CFBE30EB0729Q35766718-CEFB1502-3A33-4B68-BC0C-543BD0CD4A1CQ36157163-FB589BA0-2D99-4B26-86E4-3E4B25012D4BQ36157233-56777821-AB8C-48FB-BCAA-CC82FB0F1956Q36182610-0C359386-9B16-4A09-96C0-46288F4096B2Q36608468-C414C986-B3DB-4153-8B9B-54B3079281C8Q36703516-5BA8440F-0E2C-4F8C-9637-7CD4EED3C46FQ36715911-45A0907C-D4D6-43D0-AD13-3D271C556505Q36742108-29457ACF-9427-4BE3-B8C4-854C8CFBD9FEQ36761819-AB074050-E8B6-40C5-AC03-39718D35BE50Q36792818-BB3705A7-BF52-4E29-B3B1-BBACF9A36C49Q37370651-67D36F5E-F27F-4F05-903B-E4C49A80984BQ37397003-8DB3F722-F8CB-4780-8DFF-B5E12CC9C536Q37718826-7DCC0199-0B19-41A1-9101-26B41DA1E5F9Q38199056-115EB8CF-9E4F-4FC5-AF0E-83119A0DECAFQ38366632-2419687B-DE77-4D29-A8DB-B9620BFC5244Q38604900-46E481E6-2664-4F82-8350-C3C2A2668D0CQ38777460-638D242B-B060-4055-88FB-222F07D1A698Q39306717-A3557B67-6096-43E4-856B-764346639AD1Q39632454-94FD7311-8813-4C2C-8AC1-81A75FDED009Q40129891-7A73BE1D-A7A4-42AF-8913-EE6BE1EA65B2Q41200444-8B4CCBFA-DAB5-4971-9DBE-28D1BDE52B34Q42175192-9FD9D481-8CFF-40EA-BDC7-8B0DE982568AQ45235834-CB69D1B5-0ACF-400D-B376-4FF585621C5CQ46788345-E2BE5562-25D1-4AE3-A872-565438567DBCQ47144269-8B3B55E5-A6FF-483D-AE11-5B29D2ED097EQ47211374-D5460A44-B6D9-47D6-94B5-4D118B4C41AAQ48551157-C8AC406A-3DD8-4C14-A093-5708AD02FC06Q49790702-2C8593D7-BC92-4612-B930-EC8A41355932Q53346369-DDFFB55F-9FF5-49C9-9C81-FE90A6252261Q54179395-C5C6461D-04CE-4521-A0B7-975FEA1ABDDAQ58798385-6FFA4CE2-8677-446D-9C2E-593DF4EB2A83
P2860
Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Randomized trial of myeloablat ...... sus busulfan plus fludarabine.
@en
Randomized trial of myeloablat ...... sus busulfan plus fludarabine.
@nl
type
label
Randomized trial of myeloablat ...... sus busulfan plus fludarabine.
@en
Randomized trial of myeloablat ...... sus busulfan plus fludarabine.
@nl
prefLabel
Randomized trial of myeloablat ...... sus busulfan plus fludarabine.
@en
Randomized trial of myeloablat ...... sus busulfan plus fludarabine.
@nl
P2093
P356
P1476
Randomized trial of myeloablat ...... sus busulfan plus fludarabine.
@en
P2093
Dae-Young Kim
Gyeong-Won Lee
Hun Mo Ryoo
Jae-Hoo Park
Je-Hwan Lee
Jung-Hee Lee
Kyoo-Hyung Lee
Min Kyoung Kim
Myung Soo Hyun
P304
P356
10.1200/JCO.2011.40.2362
P407
P577
2012-11-05T00:00:00Z